Connect with us

Hi, what are you looking for?

science

A common medicine for obesity that reduces the risk of developing diabetes. There are studies – Zdrowie Wprost

A common medicine for obesity that reduces the risk of developing diabetes.  There are studies - Zdrowie Wprost

It is estimated that around 800 million people worldwide are obese. One in four Poles is obese, and in 2018 there were 1.3 million adult men and 1.6 million adult women among those with diabetes. Researchers at the University of Alabama at Birmingham investigated how this happens semaglutide – Obesity medicine – reduces the risk of developing type 2 diabetes.

Semaglutide – what does it work for?


semaglutide It is a drug previously used to treat diabetes that has already been developed, recently approved for the treatment of obesity in the United States and provisionally in the United Kingdom. In Poland, it is registered as a drug for type 2 diabetes, but it is known that it is used outside official indications by people who want to lose weight.

Effective treatment for obesity


semaglutide It is considered one of the most effective drugs in the treatment of obesity. It is an analog of human glucagon-like peptide-1 (GLP-1), that is, the hormone responsible for stimulating glucose-dependent insulin secretion. It reduces the secretion of glucose from the liver and delays gastric emptying, which reduces appetite. It can be injected or taken orally.

Dr. W. said. who led the study.

What was the search for?

Scientists investigated whether semaglutide could reduce the risk of developing diabetes. The 1961 study was overweight or obese. The experiment lasted 68 weeks. All received weekly injections of 2.4 mg semaglutide for 20 weeks. They then continued to receive semaglutide or were transferred to the placebo group for the next 48 weeks.

See also  Police in Zielona Góra: a police pilot for the health of a wounded man

risk of diabetes

The researchers attempted to predict the participants’ risk of developing type 2 diabetes over the next 10 years based on their stage of cardiovascular disease development (CMDS). They’ve previously shown that it’s an accurate measure of type 2 diabetes risk. Their studies used the logarithm of a patient’s gender, age, race, body mass index, and blood pressure, as well as blood glucose, HDL cholesterol and triglycerides. Semaglutide has been found to reduce the risk of developing diabetes by more than 60 percent. In obese patients, the number is similar, whether the patient has diabetes or normal blood sugar levels. However, they noted that long-term treatment was required to maintain benefits.


Read also:
High blood sugar? Check the signals your body is sending you

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Tech

Another person familiar with Sony’s plans confirms the killer news for PS5 owners. Horizon Forbidden West is not expected to appear on the market...

World

The British government has canceled a recommendation to avoid travel to and from the eight regions most affected by the Indian coronavirus variant altogether....

Economy

It looks like Tesla wants to use lasers instead of standard wipers in the future. I applied for a patent for this solution. The...

Economy

Farmer reveals government plans for CPK The farmer who issued the documents is a member of the social council of the CPK. As he...